Matches in SemOpenAlex for { <https://semopenalex.org/work/W2322889534> ?p ?o ?g. }
Showing items 1 to 56 of
56
with 100 items per page.
- W2322889534 abstract "Background: Trastuzumab (T) is indicated for the adjuvant treatment of HER2-overexpressing breast cancer (BC). We report the results of a retrospective study of patient-reported outcomes (PROs) for patients who received T plus chemotherapy followed by T monotherapy or T as a single-agent. Methods: Included in this analysis were 210 patients with early HER2+ BC treated in community oncology practices affiliated with ACORN Research, who completed a 38-item symptom assessment scale, the Patient Care Monitor (PCM). Treatment regimens were classified as: combination chemotherapy followed by T monotherapy: doxorubicin, cyclophosphamide, paclitaxel [n=74] or docetaxel [n=18] and T (AC→TH/ACTH) (n=92); docetaxel, carboplatin, and T (TCH) (n = 38); or “Other” chemotherapy/T (n=47); or T only (n=33). Medical records were abstracted and symptom burden was measured by PCM index scores for: Physical Symptoms, Treatment Side Effects, Distress, Despair, Impaired Ambulation, and Impaired Performance. Linear mixed models were used to examine change in PCM index scores over time, controlling for first line chemotherapy group and relevant covariates. Results: Patients were 66% Caucasian and 28% African American. The mean age of, this cohort was 56.0 years (range=31-85 years). Demographic and disease characteristic s did not differ among the four treatment regimens except patients treated with AC→TH/ACTH tended to have higher stage of disease at time of diagnosis. Among patients on combination chemotherapy, median time on active chemotherapy was 3.5 months. Patients were observed for a median of 12.5 months. Impaired Ambulation, Impaired Performance, and General Physical Symptoms worsened over the course of active chemotherapy (p Discussion: Functioning and physical symptom burden tended to worsen during active chemotherapy and to improve when active chemotherapy stopped. TCH was associated with more gradual improvement in symptom burden than AC→TH/ACTH and the “Other” combination group. Most patients treated with combination chemotherapy showed symptom burden similar to those treated with T only once they transitioned to T monotherapy as follow-up treatment. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P5-12-04." @default.
- W2322889534 created "2016-06-24" @default.
- W2322889534 creator A5000305488 @default.
- W2322889534 creator A5012107756 @default.
- W2322889534 creator A5019132733 @default.
- W2322889534 creator A5034290129 @default.
- W2322889534 creator A5070935006 @default.
- W2322889534 creator A5072015843 @default.
- W2322889534 creator A5084654434 @default.
- W2322889534 date "2010-12-15" @default.
- W2322889534 modified "2023-09-27" @default.
- W2322889534 title "Abstract P5-12-04: Symptom Burden Declines When Breast Cancer Patients Treated with Adjuvant Trastuzumab/Combination Chemotherapy Regimens Enter Trastuzumab Monotherapy Follow-Up" @default.
- W2322889534 doi "https://doi.org/10.1158/0008-5472.sabcs10-p5-12-04" @default.
- W2322889534 hasPublicationYear "2010" @default.
- W2322889534 type Work @default.
- W2322889534 sameAs 2322889534 @default.
- W2322889534 citedByCount "0" @default.
- W2322889534 crossrefType "proceedings-article" @default.
- W2322889534 hasAuthorship W2322889534A5000305488 @default.
- W2322889534 hasAuthorship W2322889534A5012107756 @default.
- W2322889534 hasAuthorship W2322889534A5019132733 @default.
- W2322889534 hasAuthorship W2322889534A5034290129 @default.
- W2322889534 hasAuthorship W2322889534A5070935006 @default.
- W2322889534 hasAuthorship W2322889534A5072015843 @default.
- W2322889534 hasAuthorship W2322889534A5084654434 @default.
- W2322889534 hasConcept C121608353 @default.
- W2322889534 hasConcept C126322002 @default.
- W2322889534 hasConcept C141071460 @default.
- W2322889534 hasConcept C143998085 @default.
- W2322889534 hasConcept C2776694085 @default.
- W2322889534 hasConcept C2776755627 @default.
- W2322889534 hasConcept C2778239845 @default.
- W2322889534 hasConcept C2779786085 @default.
- W2322889534 hasConcept C2781190966 @default.
- W2322889534 hasConcept C2781451048 @default.
- W2322889534 hasConcept C530470458 @default.
- W2322889534 hasConcept C71924100 @default.
- W2322889534 hasConceptScore W2322889534C121608353 @default.
- W2322889534 hasConceptScore W2322889534C126322002 @default.
- W2322889534 hasConceptScore W2322889534C141071460 @default.
- W2322889534 hasConceptScore W2322889534C143998085 @default.
- W2322889534 hasConceptScore W2322889534C2776694085 @default.
- W2322889534 hasConceptScore W2322889534C2776755627 @default.
- W2322889534 hasConceptScore W2322889534C2778239845 @default.
- W2322889534 hasConceptScore W2322889534C2779786085 @default.
- W2322889534 hasConceptScore W2322889534C2781190966 @default.
- W2322889534 hasConceptScore W2322889534C2781451048 @default.
- W2322889534 hasConceptScore W2322889534C530470458 @default.
- W2322889534 hasConceptScore W2322889534C71924100 @default.
- W2322889534 hasLocation W23228895341 @default.
- W2322889534 hasOpenAccess W2322889534 @default.
- W2322889534 hasPrimaryLocation W23228895341 @default.
- W2322889534 isParatext "false" @default.
- W2322889534 isRetracted "false" @default.
- W2322889534 magId "2322889534" @default.
- W2322889534 workType "article" @default.